Journal Article Summary
The article focuses on the management of heavy menstrual bleeding (HMB) in women who are on anticoagulation therapy. This topic is significant because HMB affects approximately 70% of menstruating women taking oral anticoagulants, which can lead to serious complications such as iron deficiency anemia and a decline in quality of life. Understanding how to effectively manage HMB in this population is essential for maintaining both menstrual health and the safety of anticoagulation treatment.
The study reviews various treatment options for HMB in women on anticoagulants, highlighting that hormone therapies, such as the levonorgestrel intrauterine system and progesterone-based treatments, are effective in reducing blood loss. The article notes that while some anticoagulants like apixaban and dabigatran carry a lower risk of HMB compared to rivaroxaban, patients still need to be monitored for symptoms. It emphasizes the importance of evaluating patients for iron deficiency and anemia and suggests that in rare cases, more invasive procedures like endometrial ablation may be necessary.
However, the article also points out limitations, such as the potential risks associated with altering anticoagulation therapy, which can significantly increase the chance of blood clots. It stresses the importance of not skipping doses of anticoagulants, as this can lead to serious health risks. Patients are encouraged to discuss any symptoms of heavy menstrual bleeding with their healthcare providers to ensure appropriate management and to explore treatment options that balance the risks of anticoagulation with the need to control menstrual bleeding.
Medication Safety Note
This journal article summary is provided for educational purposes only and is not medical advice. Always consult a licensed healthcare professional before starting, stopping, or changing any medication.
Article Cited
- Samuelson Bannow Bethany. Management of heavy menstrual bleeding on anticoagulation. Hematology: the American Society of Hematology Education Program 2020. DOI: 10.1182/hematology.2020000138. PMID: 33275699. PMCID: PMC7727540.
Featured Pill Pals Product
OPill (O-Pill) Norgestrel Tablets 0.075 mg Daily Oral Contraceptive (Birth Control) --- Perrigo --- Over The Counter
OPill (O-Pill) Norgestrel Tablets 0.075 mg Daily Oral Contraceptive (Birth Control) — Perrigo — Over The Counter is available through Pill Pals Pharmacy with cash-pay pharmacy pricing and free shipping where available. This is an Over The Counter Product, so no prescription is required.However, your prescriber can still write for it as a prescription, if desired.
